Cancer Research and Treatment

Volume 37(2); April 2005

Review Article

Chemotherapy for Advanced Gastric Cancer: Slow but Further Progress: Yeul Hong Kim; Cancer Res Treat. 2005;37(2):79-86. Published online April 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.2.79

Gastric cancer remains a significant problem in terms of global health, and is the most common cancer in Korea. Surgery is the only potentially curative treatment for localized gastric cancer, but most cases present at an advanced stage. Randomized trials have demonstrated that chemotherapy for advanced gastric cancer improves the quality of life and extends survival, by 4~6 months, compared with best supportive care alone. Single agents with a proven activity in a first-line setting include 5-fluorouracil (5-FU), doxorubicin, mitomycin C, cisplatin, taxanes (docetaxel and paclitaxel) and oral fluoropyrimidines (capecitabine and TS-1). Based on the results from several large scale randomized trials, FP (5-FU/cisplatin) and ECF (epirubicin/cisplatin/5-FU) combinations are the most widely used regimen against advanced gastric cancer. Phase II studies of the FP and ECF combination reported a 40~51% response rate in previously untreated patients, and this regimen also produced a significantly higherresponse rate than the FAM (5-FU/doxorubicin/ mitomycin) and FAMTX (5-FU/doxorubicin/methotrexate) regimens, respectively. However, significant treatment related-toxicities and discomfort were reported from ECF, which prevents this combination from becoming the standard treatment regimen. While no one combination chemotherapy regimen is accepted as the standard for advanced gastric cancer, FP is currently considered a suitable reference regimen worldwide. New agents, such as taxane, irinotecan and oxaliplatin, combined with old agents, such as cisplatin and 5-FU, are currently under evaluation to further improve treatment outcomes. Also, oral 5-FU prodrugs are replacing the cumbersome 5-FU long-term infusion due to its convenience and superior toxicity profile. However, the low complete response rate and short response duration are still the main obstacles in the chemotherapy for gastric cancer. Only large scale comparative clinical trials will give clues to improve the results of gastric cancer treatments.

Citations

Citations to this article as recorded by

CircSOD2 polarizes macrophages towards the M1 phenotype to alleviate cisplatin resistance in gastric cancer cells by targeting the miR-1296/STAT1 axis
Bing Qu, Jiasheng Liu, Zhiyang Peng, Zhe Xiao, Shijun Li, Jianguo Wu, Shengbo Li, Jianfei Luo
Gene.2023; 887: 147733. CrossRef
Induction of apoptotic DNA fragmentation mediated by mitochondrial pathway with caspase-3-dependent BID cleavage in human gastric cancer cells by a new nitroxyl spin-labeled derivative of podophyllotoxin
Yu-Jie Yang, She-Ning Qi, Rui-Yue Shi, Jun Yao, Li-Sheng Wang, Hu-Qin Yuan, Yuan-Xue Jing
Biomedicine & Pharmacotherapy.2017; 90: 131. CrossRef
Effect of First Line Gastric Cancer Chemotherapy Regime on the AGS Cell Line - MTT Assay Results
Reza Alizadeh-Navaei, Alireza Rafiei, Saeid Abedian-Kenari, Hossein Asgarian-Omran, Reza Valadan, Akbar Hedayatizadeh-Omran
Asian Pacific Journal of Cancer Prevention.2016; 17(1): 131. CrossRef
Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
David Propper, Keith Jones, D. Alan Anthoney, Wasat Mansoor, Daniel Ford, Martin Eatock, Roshan Agarwal, Michiyasu Inatani, Tomohisa Saito, Masaichi Abe, T. R. Jeffry Evans
BMC Cancer.2016;[Epub] CrossRef
Clinical Outcome of Doublet and Triplet Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
Ju Seok Kim, Sun Hyung Kang, Hee Seok Moon, Jae Kyu Sung, Hyun Yong Jeong, Ji Young Sul
The Korean Journal of Gastroenterology.2016; 68(5): 245. CrossRef
Impact of Intratumoral Expression Levels of Fluoropyrimidine-Metabolizing Enzymes on Treatment Outcomes of Adjuvant S-1 Therapy in Gastric Cancer
Ji-Yeon Kim, Eun Shin, Jin Won Kim, Hye Seung Lee, Dae-Won Lee, Se-Hyun Kim, Jeong-Ok Lee, Yu Jung Kim, Jee Hyun Kim, Soo-Mee Bang, Sang-Hoon Ahn, Do Joong Park, Jong Seok Lee, Ju-Seog Lee, Hyung-Ho Kim, Keun-Wook Lee, Qing-Yi Wei
PLOS ONE.2015; 10(3): e0120324. CrossRef
Efficacy of S-1vscapecitabine for the treatment of gastric cancer: A meta-analysis
An-Bing He
World Journal of Gastroenterology.2015; 21(14): 4358. CrossRef
A Case of Gingival Candidiasis with Bone Destruction on Gastric Cancer Patient Receiving Cytotoxic Chemotherapy
Seungtaek Lim, Tae-jun Kil, Hye Ryun Kim, Seonhui Han, Sun Young Rha
Case Reports in Oncological Medicine.2014; 2014: 1. CrossRef
A phase II trial of oxaliplatin plus S-1 as a first-line chemotherapy for patients with advanced gastric cancer
Lin YANG, Yan SONG, Ai-ping ZHOU, Qiong QIN, Yihebali CHI, Jing HUANG, Jin-wan WANG
Chinese Medical Journal.2013; 126(18): 3470. CrossRef
A randomized phase II trial of S-1-oxaliplatin versus capecitabine–oxaliplatin in advanced gastric cancer
Gun Min Kim, Hei-Cheul Jeung, Sun Young Rha, Hyo Song Kim, Inkyung Jung, Byung Ho Nam, Kyung Hee Lee, Hyun Cheol Chung
European Journal of Cancer.2012; 48(4): 518. CrossRef
Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy
N. Kim, C. Park, D.J. Park, H.-H. Kim, S. Kim, Y.J. Kim, J.H. Kim, J.S. Lee, Y.-J. Bang, S.I. Khwarg, H. Choung, M.J. Lee, K.-W. Lee
Annals of Oncology.2012; 23(8): 2065. CrossRef
Interstitial lung disease caused by TS-1: a case of long-term drug retention as a fatal adverse reaction
Joong-Min Park, In Gyu Hwang, Suk-Won Suh, Kyong-Choun Chi
Journal of the Korean Surgical Society.2011; 81(6): 414. CrossRef
Oxaliplatin and Leucovorin Plus Fluorouracil Versus Irinotecan and Leucovorin Plus Fluorouracil Combination Chemotherapy as a First-line Treatment in Patients with Metastatic or Recurred Gastric Adenocarcinoma
Sun Hyung Kang, Jeong Il Kim, Hee Seok Moon, Seok Hyun Kim, Jae Kyu Sung, Byung Seok Lee, Hyun Yong Jeong
The Korean Journal of Gastroenterology.2010; 55(1): 26. CrossRef
Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer
Kyung Hee Lee, Myung Soo Hyun, Hoon-Kyo Kim, Hyung Min Jin, Jinmo Yang, Hong Suk Song, Young Rok Do, Hun Mo Ryoo, Joo Seop Chung, Dae Young Zang, Ho-Yeong Lim, Jong Youl Jin, Chang Yeol Yim, Hee Sook Park, Jun Suk Kim, Chang Hak Sohn, Soon Nam Lee
Cancer Research and Treatment.2009; 41(1): 12. CrossRef

11,090 View
68 Download
14 Crossref

Original Articles

Clinicopathological Analysis of Borrmann Type IV Gastric Cancer: Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim; Cancer Res Treat. 2005;37(2):87-91. Published online April 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.2.87

Abstract PDF PubReader ePub

Purpose

Borrmann type IV gastric cancer is often diagnosed only at an advanced stage, resulting in a prognosis poor. We performed a retrospective study of the clinical characteristics of Borrmann type IV gastric cancer and the prognostic factors affecting the survival rate in such patients.

Materials and Methods

Of 4,063 patients with all gastric cancers, 370 (9%) with Borrmann type IV gastric cancer were analyzed.

Results

The clinical characteristics of these patients included a higher incidence rate in young females, and higher rates of serosa exposure, metastasis to lymph nodes and early peritoneal dissemination. Of patients presenting with peritoneal seeding, those resected had a higher survival rate than those that were not. A univariate analysis showed that the prognostic factors affecting the survival rate following a curative resection were the location, occupied area and depth of the primary tumor, as well as the presence of lymph node metastasis and the tumor stage. A multivariate analysis indicated that the tumor location and stage were significant independent prognostic factors after a curative resection for Borrmann type IV gastric cancer.

Conclusion

In conclusion, the early diagnosis and treatment of patients with Borrmann type IV gastric cancer are essential for the better survival of these patients. Even in patients with advanced tumors, a noncurative palliative resection may improve the prognosis.

Citations

Citations to this article as recorded by

Borrmann Type IV Gastric Cancer: Computed Tomography Features and Corresponding Pathological Findings
Changfeng Ji, Yi Ma, Zhong Zheng, Song Liu, Zhengyang Zhou
Journal of Computer Assisted Tomography.2024; 48(2): 200. CrossRef
Clinicopathological and prognostic features of Borrmann type IV gastric cancer versus other Borrmann types: A unique role of signet ring cell carcinoma
Chengcai Liang, Yao Liang, Biyi Ou, Lei Yuan, Shuqiang Yuan
Saudi Journal of Gastroenterology.2023; 29(4): 240. CrossRef
PN3b as an independent risk factor for poor prognosis and peritoneal recurrence in Borrmann type IV gastric cancer: A retrospective cohort study
Yiran Chen, Yanyan Chen, Liping Wen, Laizhen Tou, Haiyong Wang, Lisong Teng
Frontiers in Surgery.2022;[Epub] CrossRef
Comparative Outcomes of Laparoscopic Gastrectomy and Open Gastrectomy for Scirrhous Gastric Cancer: A Multicenter Retrospective Cohort Study
Yusuke Fujita, Tatsuto Nishigori, Yoshio Kadokawa, Atsushi Itami, Masato Kondo, Hisahiro Hosogi, Seiichiro Kanaya, Hironori Kawada, Hiroaki Hata, Michihiro Yamamoto, Yousuke Kinjo, Eiji Tanaka, Dai Manaka, Seiji Satoh, Hiroshi Okabe, Shigeru Tsunoda, Masa
Annals of Surgery Open.2021; 2(2): e063. CrossRef
Are Borrmann’s Types of Advanced Gastric Cancer Distinct Clinicopathological and Molecular Entities? A Western Study
Cristina Díaz del Arco, Luis Ortega Medina, Lourdes Estrada Muñoz, Elena Molina Roldán, M. Ángeles Cerón Nieto, Soledad García Gómez de las Heras, M. Jesús Fernández Aceñero
Cancers.2021; 13(12): 3081. CrossRef
Borrmann Type IV Gastric Cancer: Focus on the Role of Gastrectomy
Chengcai Liang, Guoming Chen, Baiwei Zhao, Haibo Qiu, Wei Li, Xiaowei Sun, Zhiwei Zhou, Yingbo Chen
Journal of Gastrointestinal Surgery.2020; 24(5): 1026. CrossRef
Subtotal gastrectomy combined with chemotherapy: An effective therapy for patients with circumscribed Borrmann type IV gastric cancer
Hai-Bo Huang, Zi-Ming Gao, An-Qi Sun, Wei-Tian Liang, Kai Li
World Journal of Gastrointestinal Oncology.2020; 12(11): 1325. CrossRef
Role of Cancer-Associated Fibroblast in Gastric Cancer Progression and Resistance to Treatments
In-Hye Ham, Dagyeong Lee, Hoon Hur
Journal of Oncology.2019; 2019: 1. CrossRef
Endoscopic ultrasound‑guided fine‑needle aspiration biopsy for diagnosis of gastric linitis plastica with negative malignant endoscopy biopsies
Yingjian Ye, Shiyun Tan
Oncology Letters.2018;[Epub] CrossRef
Muscle RAS oncogene homolog (MRAS) recurrent mutation in Borrmann type IV gastric cancer
Makiko Yasumoto, Etsuko Sakamoto, Sachiko Ogasawara, Taro Isobe, Junya Kizaki, Akiko Sumi, Hironori Kusano, Jun Akiba, Takuji Torimura, Yoshito Akagi, Hiraku Itadani, Tsutomu Kobayashi, Shinichi Hasako, Masafumi Kumazaki, Shinji Mizuarai, Shinji Oie, Hiro
Cancer Medicine.2017; 6(1): 235. CrossRef
Endoscopic ultrasound-guided cutting of holes and deep biopsy for diagnosis of gastric infiltrative tumors and gastrointestinal submucosal tumors using a novel vertical diathermic loop
Yu-Mei Liu, Xiu-Jiang Yang
World Journal of Gastroenterology.2017; 23(15): 2795. CrossRef
Clinicopathologic characteristics and prognosis of Borrmann type IV gastric cancer: a meta-analysis
Yifan Luo, Peng Gao, Yongxi Song, Jingxu Sun, Xuanzhang Huang, Junhua Zhao, Bin Ma, Yuan Li, Zhenning Wang
World Journal of Surgical Oncology.2016;[Epub] CrossRef
Borrmann type IV gastric cancer should be classified as pT4b disease
Jin-yu Huang, Zhen-ning Wang, Chun-yang Lu, Zhi-feng Miao, Zhi Zhu, Yong-xi Song, Hui-mian Xu, Ying-ying Xu
Journal of Surgical Research.2016; 203(2): 258. CrossRef
Limited significance of curative surgery in Borrmann type IV gastric cancer
Eun Young Kim, Han Mo Yoo, Kyo Young Song, Cho Hyun Park
Medical Oncology.2016;[Epub] CrossRef
An update on gastric cancer
Syed A. Ahmad, Brent T. Xia, Christina E. Bailey, Daniel E. Abbott, Beth A. Helmink, Meghan C. Daly, Ramya Thota, Cameron Schlegal, Leah K. Winer, S. Ameen Ahmad, Ali H. Al Humaidi, Alexander A Parikh
Current Problems in Surgery.2016; 53(10): 449. CrossRef
CA125 is a potential biomarker to predict surgically incurable gastric and cardia cancer
Taobo Luo, Wenhu Chen, Lifang Wang, Hongguang Zhao
Medicine.2016; 95(51): e5297. CrossRef
Undiagnosed Borrmann type IV gastric cancer despite repeated endoscopic biopsies and PET-CT examination: A case report
Fang-Qing Zhu, Hong-Jin Chu, Zhao-Hua Gong, Feng-Cai Du, Jian Chen, Li-Xin Jiang
Oncology Letters.2016; 12(2): 1485. CrossRef
Variable Endoscopic Findings and Clinicopathological Characteristics of Borrmann Type 4 Advanced Gastric Cancer
Ji Young Chang, Ki-Nam Shim, Chung Hyun Tae, A Reum Choe, Chang Mo Moon, Seong-Eun Kim, Hye-Kyung Jung, Sung-Ae Jung
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2015; 15(3): 166. CrossRef
Survival Benefit of Palliative Gastrectomy in Gastric Cancer Patients with Peritoneal Metastasis
Masanori Tokunaga, Masanori Terashima, Yutaka Tanizawa, Etsuro Bando, Taiichi Kawamura, Hirofumi Yasui, Narikazu Boku
World Journal of Surgery.2012; 36(11): 2637. CrossRef
Risk Stratification for Serosal Invasion Using Preoperative Predictors in Patients with Advanced Gastric Cancer
Sung-Sil Park, Jae-Seok Min, Kyu-Jae Lee, Sung-Ho Jin, Sunhoo Park, Ho-Yoon Bang, Hwang-Jong Yu, Jong-Inn Lee
Journal of Gastric Cancer.2012; 12(3): 149. CrossRef
An Insufficient Preoperative Diagnosis of Borrmann Type 4 Gastric Cancer in Spite of EMR
Jae Bong Ahn, Tae Kyung Ha, Hang Rak Lee, Sung Joon Kwon
Journal of Gastric Cancer.2011; 11(1): 59. CrossRef
Gastric carcinoma: when is palliative gastrectomy justified?
Hubert Scheidbach, Hans Lippert, Frank Meyer
Oncology Reviews.2010; 4(2): 127. CrossRef
Prognostic Factors in Gastric Cancer Patients with Peritoneal Carcinomatosis
Hyun Il Kim, Tae Kyung Ha, Sung Joon Kwon
Journal of Gastric Cancer.2010; 10(3): 126. CrossRef
Prognosis of pN3 Stage Gastric Cancer
Jung Ryun Ahn, Minkyu Jung, Chan Kim, Min Hee Hong, Hong Jae Chon, Hye Ryun Kim, Hei-Cheul Jeung, Woo Jin Hyung, Sung Sook Lee, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha
Cancer Research and Treatment.2009; 41(2): 73. CrossRef
Borrmann Type IV: An Independent Prognostic Factor for Survival in Gastric Cancer
Ji Yeong An, Tae Ho Kang, Min Gew Choi, Jae Hyung Noh, Tae Sung Sohn, Sung Kim
Journal of Gastrointestinal Surgery.2008; 12(8): 1364. CrossRef
Prognostic Factors for Advanced Gastric Cancer: Stage-stratified Analysis of Patients who Underwent Curative Resection
Joong-Min Park, Woo-Sang Ryu, Jong-Han Kim, Sung-Soo Park, Seung-Joo Kim, Chong-Suk Kim, Young-Jae Mok
Cancer Research and Treatment.2006; 38(1): 13. CrossRef

11,347 View
104 Download
26 Crossref

Retrospective Analysis of the Treatment Results for Patients with Squamous Cell Carcinoma of Tonsil: Ah Ram Chang, Hong-Gyun Wu, Charn Il Park, Kwang-Hyun Kim, Myung-Whun Sung, Dae-Seog Heo; Cancer Res Treat. 2005;37(2):92-97. Published online April 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.2.92

Abstract PDF PubReader ePub

Purpose

There has been no definitive randomized study to identify the optimal therapeutic regimen for treating squamous cell carcinoma of tonsil. The purpose of this study was to retrospectively evaluate the treatment outcome according to various combinations of surgery, radiation therapy and chemotherapy.

Materials and Methods

Fifty-six patients with tonsillar carcinoma, who were treated at Seoul National University Hospital from March 1985 to August 2001, were the subjects of this study. Twenty-one patients received surgery followed by radiation therapy (SRT), 16 patients underwent radiation therapy alone (RT), and 19 patients received neoadjuvant chemotherapy and radiation therapy (CRT). The median radiation dose was 66.6 Gy for the SRT group and 70.2 Gy for the RT and CRT groups. Surgery comprised extended tonsillectomy and modified radical neck dissection of the involved neck. Cisplatin and 5-fluorouracil were used every three weeks for 3 cycles in the SRT group. The median follow-up was 73.2 months.

Results

The distribution of T-stage was 4 cases of T1, 14 cases of T2, 1 case of T3 and 2 cases of T4 staging in the SRT group, 2 cases of T1, 6 cases of T2, 5 cases of T3 and 3 cases of T4 staging in the RT group and 0 cases of T1, 7 cases of T2, 9 cases of T3 and 3 cases of T4 staging in the CRT group. The distribution of N-stage was 5 cases of N0, 2 cases of N1, 13 cases of N2 and 1 case of N3 staging in the SRT group, 6 cases of N0, 5 cases of N1, 5 cases of N2 and 0 cases of N3 staging in the RT group, and 2 cases of N0, and 7 cases of N1, 9 cases of N2 and 1 case of N3 staging in the CRT group. The five-year overall survival rate (OSR) for all patients was 78%. The five-year OSR was 80% for the SRT group, 71% for the RT group, and 80% for the CRT group (p=ns). The five-year disease-free survival rate was 93% for the CRT group and 71% for the RT group (p=0.017). Four patients developed local failure and one patient failed at a regional site in the RT group, and one patient failed at a primary site in the CRT group. The five-year DFS was 84% for patients who had undergone neck dissection and 76% for patients who had not undergone neck dissection (p=ns). Treatment-related complications of grade 3 or 4 occurred in 15 patients, and the incidence of complication was not different between each of the treatment methods.

Conclusion

Although the patients with more advanced T stage were included in the RT and CRT groups, the OSR was not statistically different according to the treatment methods. In the radical radiation therapy group, the addition of neoadjuvant chemotherapy showed an improvement in the disease-free survival. Because of the retrospective nature of our study and the small number of patients, this study cannot draw any definite conclusions, but it suggests that radiation therapy with chemotherapy can be a good alternative option for squamous cell carcinoma of tonsil. Controlled randomized study is necessary to confirm this hypothesis.

Citations

Citations to this article as recorded by

Long-term results of ipsilateral radiotherapy for tonsil cancer
Tae Ryool Koo, Hong-Gyun Wu
Radiation Oncology Journal.2013; 31(2): 66. CrossRef
Definitive Radiotherapy versus Postoperative Radiotherapy for Tonsil Cancer
Tae Ryool Koo, Hong-Gyun Wu, J. Hun Hah, Myung-Whun Sung, Kwang-Hyun Kim, Bhumsuk Keam, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Dae-Seog Heo, Charn Il Park
Cancer Research and Treatment.2012; 44(4): 227. CrossRef
Treatment outcome in the residually positive neck after definitive chemotherapy and irradiation
Laura M. Dooley, Kevin L. Potts, Liz D. Wilson, Zachary J. Cappello, Jeffrey M. Bumpous
The Laryngoscope.2011; 121(8): 1656. CrossRef
EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil
Im Il Na, Hye Jin Kang, Soo Youn Cho, Jae Soo Koh, Jin Kyung Lee, Byeong Cheol Lee, Guk Haeng Lee, Yong Sik Lee, Hyung Jun Yoo, Baek-Yeol Ryoo, Sung Hyun Yang, Yoon Sang Shim
European Journal of Cancer.2007; 43(3): 520. CrossRef

10,518 View
47 Download
4 Crossref

Loss of DNA-dependent Protein Kinase Catalytic Subunit (DNA-PKcs) Expression in Gastric Cancers: Hye Seung Lee, Han-Kwang Yang, Woo Ho Kim, Gheeyoung Choe; Cancer Res Treat. 2005;37(2):98-102. Published online April 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.2.98

Abstract PDF PubReader ePub

Purpose

DNA-PKcs is one of the DNA repair genes. It was recently found that hyperplasia and dysplasia of the intestinal mucosa and the production of aberrant crypt foci were developed in DNA-PKcs-null mice, and this suggests a suppressive role for DNA-PKcs in tumorigenesis.

Materials and Methods

To investigate the possible relationship between the clinico-pathologic characteristics and the survival of gastric cancer patients, the expression status of DNA-PKcs was determined in 279 consecutive gastric cancers. Immunohistochemical analysis was performed to evaluate the expression levels of DNA-PKcs protein by using the tissue array method.

Results

Out of 279 consecutive gastric cancers, 63 cases (22.6%) showed the loss of DNA-PKcs expression. The loss of DNA-PKcs expression was significantly associated with advanced cancer (p<0.001), lymphatic invasion (p=0.001), lymph node metastasis (p=0.009), and advanced pTNM stage (p=0.009). Univariate survival analysis revealed that patients with the loss of DNA-PKcs expression had significantly poorer survival than those patients with intact DNA-PKcs expression (p=0.004). Moreover, the loss of DNA-PKcs expression was identified to correlate with a lower survival in the subgroup of stage I gastric cancer patients (p=0.037).

Conclusion

The loss of DNA-PKcs expression was found in 23% of human gastric cancers and this was identified to significantly correlate with poor patient survival, especially for stage I gastric cancer patients.

Citations

Citations to this article as recorded by

Shaping DNA damage responses: Therapeutic potential of targeting telomeric proteins and DNA repair factors in cancer
Yu Bin Ng, Semih Can Akincilar
Current Opinion in Pharmacology.2024; 76: 102460. CrossRef
An exosome mRNA-related gene risk model to evaluate the tumor microenvironment and predict prognosis in hepatocellular carcinoma
Zhonghai Du, Xiuchen Han, Liping Zhu, Li Li, Leandro Castellano, Justin Stebbing, Ling Peng, Zhiqiang Wang
BMC Medical Genomics.2024;[Epub] CrossRef
Secrets of DNA-PKcs beyond DNA repair
Sydney Camfield, Sayan Chakraborty, Shailendra Kumar Dhar Dwivedi, Pijush Kanti Pramanik, Priyabrata Mukherjee, Resham Bhattacharya
npj Precision Oncology.2024;[Epub] CrossRef
Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present)
Suwen Hu, Zi Hui, Frédéric Lirussi, Carmen Garrido, Xiang-Yang Ye, Tian Xie
Expert Opinion on Therapeutic Patents.2021; 31(5): 435. CrossRef
Role of PRKDC in cancer initiation, progression, and treatment
Yu Chen, Yi Li, Jiani Xiong, Bin Lan, Xuefeng Wang, Jun Liu, Jing Lin, Zhaodong Fei, Xiaobin Zheng, Chuanben Chen
Cancer Cell International.2021;[Epub] CrossRef
Comparative proteomic analysis of different stages of breast cancer tissues using ultra high performance liquid chromatography tandem mass spectrometer
Abdullah Saleh Al-wajeeh, Salizawati Muhamad Salhimi, Majed Ahmed Al-Mansoub, Imran Abdul Khalid, Thomas Michael Harvey, Aishah Latiff, Mohd Nazri Ismail, John Matthew Koomen
PLOS ONE.2020; 15(1): e0227404. CrossRef
PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
Kien Thiam Tan, Chun-Nan Yeh, Yu-Chan Chang, Jen-Hao Cheng, Wen-Liang Fang, Yi-Chen Yeh, Yu-Chao Wang, Dennis Shin-Shian Hsu, Chiao-En Wu, Jiun-I Lai, Peter Mu-Hsin Chang, Ming-Han Chen, Meng-Lun Lu, Shu-Jen Chen, Yee Chao, Michael Hsiao, Ming-Huang Chen
Journal for ImmunoTherapy of Cancer.2020; 8(1): e000485. CrossRef
DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions
Michaela Medová, Matúš Medo, Lusine Hovhannisyan, Carmen Muñoz-Maldonado, Daniel M. Aebersold, Yitzhak Zimmer
Pharmacology & Therapeutics.2020; 215: 107617. CrossRef
DNA-dependent protein kinase: Epigenetic alterations and the role in genomic stability of cancer
Vazhappilly Cijo George, Shabbir Ahmed Ansari, Vipin Shankar Chelakkot, Ayshwarya Lakshmi Chelakkot, Chaithanya Chelakkot, Varsha Menon, Wafaa Ramadan, Kannatt Radhakrishnan Ethiraj, Raafat El-Awady, Theodora Mantso, Melina Mitsiogianni, Mihalis I. Panagi
Mutation Research/Reviews in Mutation Research.2019; 780: 92. CrossRef
Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer
Xiang Zhang, Yanlin Wang, Yuan Ning
Urologic Oncology: Seminars and Original Investigations.2017; 35(3): 111.e15. CrossRef
Ab initio and QSAR study of several etoposides as anticancer drugs: Solvent effect
R. Sayyadi kord Abadi, A. Alizadehdakhel, S. Dorani Shiraz
Russian Journal of Physical Chemistry B.2017; 11(2): 307. CrossRef
The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer
Brock Sishc, Anthony Davis
Cancers.2017; 9(7): 81. CrossRef
PRKDC regulates chemosensitivity and is a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients
Gang Sun, Le Yang, Chao Dong, Bin Ma, Meihui Shan, Binlin Ma
Oncology Reports.2017; 37(6): 3536. CrossRef
DNA-PKcs activates the Chk2–Brca1 pathway during mitosis to ensure chromosomal stability
Z Shang, L Yu, Y-F Lin, S Matsunaga, C-Y Shen, B P C Chen
Oncogenesis.2014; 3(2): e85. CrossRef
Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers
Tarek Abdel-Fatah, Arvind Arora, Devika Agarwal, Paul Moseley, Christina Perry, Nicola Thompson, Andrew R. Green, Emad Rakha, Stephen Chan, Graham Ball, Ian O. Ellis, Srinivasan Madhusudan
Breast Cancer Research and Treatment.2014; 146(2): 309. CrossRef
Predictive factors for the sensitivity of radiotherapy and prognosis of esophageal squamous cell carcinoma
Shaobin Wu, Xianwei Wang, Jin-Xiang Chen, Yuxiang Chen
International Journal of Radiation Biology.2014; 90(5): 407. CrossRef
DNA-PKcs and Ku70 are Predictive Markers for Poor Prognosis of Patients With Gall Bladder Malignancies
Feng Ren, Zhu-lin Yang, Xingguo Tan, Dongcai Liu, Qiong Zou, Yuan Yuan, Jinghe Li, Lufeng Liang, Guixiang Zeng, Senlin Chen
Applied Immunohistochemistry & Molecular Morphology.2014; 22(10): 741. CrossRef
Deregulation of DNA-dependent protein kinase catalytic subunit contributes to human hepatocarcinogenesis development and has a putative prognostic value
M Evert, M Frau, M L Tomasi, G Latte, M M Simile, M A Seddaiu, A Zimmermann, S Ladu, T Staniscia, S Brozzetti, G Solinas, F Dombrowski, F Feo, R M Pascale, D F Calvisi
British Journal of Cancer.2013; 109(10): 2654. CrossRef
Expression of DNA-PKcs and BRCA1 as prognostic indicators in nasopharyngeal carcinoma following intensity-modulated radiation therapy
JIAO YANG, XIMING XU, YANRONG HAO, JIAXIN CHEN, HEMING LU, JIAN QIN, LUXING PENG, BIAO CHEN
Oncology Letters.2013; 5(4): 1199. CrossRef
Identification of genes with a correlation between copy number and expression in gastric cancer
Lei Cheng, Ping Wang, Sheng Yang, Yanqing Yang, Qing Zhang, Wen Zhang, Huasheng Xiao, Hengjun Gao, Qinghua Zhang
BMC Medical Genomics.2012;[Epub] CrossRef
Lack of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) is accompanied by increased CK2α′ levels
Birgitte B. Olsen, Ulrike Fischer, Tine L. Rasmussen, Matthias Montenarh, Eckart Meese, Gerhard Fritz, Olaf-Georg Issinger
Molecular and Cellular Biochemistry.2011; 356(1-2): 139. CrossRef
The association of DNA-dependent protein kinase activity of peripheral blood lymphocytes with prognosis of cancer
M Someya, K-i Sakata, Y Matsumoto, R P Kamdar, M Kai, M Toyota, M Hareyama
British Journal of Cancer.2011; 104(11): 1724. CrossRef
Tissue Array Methods for High-throughput Clinicopathologic Research
Hye Seung Lee, Woo Ho Kim
Cancer Research and Treatment.2006; 38(1): 1. CrossRef

10,107 View
64 Download
23 Crossref

Mast Cell and Macrophage Counts and Microvessel Density in Invasive Breast Carcinoma-Comparison Analysis with Clinicopathological Parameters: Gui Young Kwon, Sang Dae Lee, Eon Sub Park; Cancer Res Treat. 2005;37(2):103-108. Published online April 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.2.103

Abstract PDF PubReader ePub

Purpose

The purpose of this study was to evaluate the clinicopathological significance of the microvessel density and macrophage and mast cell counts in invasive breast carcinomas.

Materials and Methods

45 invasive breast carcinomas were immunohistochemically stained with the endothelial antigen, CD34, and macrophage marker, CD68. 0.1% toluidine blue was used to highlight mast cells. The microvessel and mast cell counts were performed at ×200 magnification and the macrophages at ×400 magnification.

Results

With the 45 invasive breast carcinomas, there were no statistically significant associations between the mast cell, macrophage and microvessel counts and the tumor size and lymph node status. ER and PR negative mast cells infiltrated more than in cases of positive stati, with statistical significance (p-value=0.010 and 0.005, respectively). The macrophage counts were negatively correlated with the PR status (p-value=0.030). With respect to the c-erbB-2 status, there was no significance correlation with the mast cell, macrophage and microvessel counts. The mast cell counts showed significantly positive correlation with the microvessel counts in the invasive breast carcinomas (p-value=0.015). In a comparison of the macrophage counts with the microvessel counts, a positive tendency for both parameters, but without statistical significance (p-value=0.310).

Conclusion

Increasing numbers of mast cells and macrophages were recruited in invasive breast carcinomas, which contribute to angiogenesis. The microvessel density in invasive breast carcinomas had no statistically significant association with the tumor size, lymph node status, and histological grade, presence of DCIS component, estrogen/progesterone receptor status and cerbB-2 status. The evaluation of angiogenesis using these methods is not thought to provide an independent clinicopathological factor in invasive breast carcinomas.

Citations

Citations to this article as recorded by

Correlation of microvessel density with histopathological parameters of carcinoma breast
Aditi V. Goyal, Samarth Shukla, Sourya Acharya, Sunita Vagha, Suhas Jajoo
Indian Journal of Medical Research.2023; 158(4): 417. CrossRef
Study of microvessel density in breast carcinoma with CD34 immunostaining – An institutional experience in Puducherry
Vigneswaramoorthi Vinayagamoorthi, Erli Amel Ivan, G. Revathi, V. Sriram, Ramya Gandhi, Reenaa Mohan, Roy Arokiam
Journal of Current Research in Scientific Medicine.2023; 9(2): 93. CrossRef
Few, but Efficient: The Role of Mast Cells in Breast Cancer and Other Solid Tumors
Maria Teresa Majorini, Mario Paolo Colombo, Daniele Lecis
Cancer Research.2022; 82(8): 1439. CrossRef
Quantitative mast cell analysis and hormone receptor study (ER, PR and HER2/neu) in invasive carcinoma of breast
RamaD Pyla, RM Potekar, VijayalaxmiS Patil, AnilK Reddy, KV Sathyashree
Indian Journal of Pathology and Microbiology.2020; 63(2): 200. CrossRef
Tumor associated mast cells: biological roles and therapeutic applications
Shikha Saxena, Anil Singh, Priyanka Singh
Anatomy & Cell Biology.2020; 53(3): 245. CrossRef
Serum uPAR as Biomarker in Breast Cancer Recurrence: A Mathematical Model
Wenrui Hao, Avner Friedman, Yi-Hsien Hsieh
PLOS ONE.2016; 11(4): e0153508. CrossRef
Genomic alterations and phenotype of large compared to small high-grade ductal carcinoma in situ
E. Shelley Hwang, Aseem Lal, Yunn-Yi Chen, Sandy DeVries, Rebecca Swain, Joe Anderson, Ritu Roy, Frederic M. Waldman
Human Pathology.2011; 42(10): 1467. CrossRef

9,017 View
65 Download
7 Crossref

Outcome and Prognostic Factors of Childhood Diffuse Brainstem Glioma: Semie Hong, Il Han Kim, Kyu Chang Wang; Cancer Res Treat. 2005;37(2):109-113. Published online April 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.2.109

Abstract PDF PubReader ePub

Purpose

The outcome and prognostic factors of brainstem glioma were evaluated following radiotherapy methods.

Materials and Methods

Between 1986 and 2001, 45 childhood patients with diffuse brainstem glioma were treated. There were 26 boys and 19 girls, with a median age of 7 years (range 3~18). The histopathological diagnoses were confirmed in 13 patients, which revealed a low-grade glioma in four patients, and high-grade glioma in the other nine. Before 1993, radiation therapy using a regime of 1.8 to 2.0 Gy once a day was performed in 16 cases; thereafter, a regimes of 1.1 or 1.5 Gy twice a day was given in 15 and 14 cases, respectively. Nine patients were treated with adjuvant chemotherapy. The response to the treatment was evaluated by the MRI findings 4 weeks after radiotherapy.

Results

After radiotherapy, the neurological deficit improved in 42 of the 45 patients (93%). The MRI responses were as follows; partial response 22/39 (56%), minimal to no response in 16/39 (41%) and tumor progression in 1/39 (3%). The median time to disease progression was 7 months, and the median survival was 12 months; the overall survival rate at 1 year was 41%. There was no significant prognostic factor for overall survival. The progression-free survival was influenced by the tumor histology (low grade vs. high grade, p=0.05) in those patients whose pathology was confirmed.

Conclusion

The radiation therapy fractionation schedule did not influence the survival. Low grade histology was a possible favorable prognostic factor of progression-free survival in pediatric brainstem glioma patients.

Citations

Citations to this article as recorded by

Unveiling the Efficacy of Gamma Knife Radiosurgery for Tectal Plate Gliomas
Nülifer Kilic Durankus, Yavuz Samanci, Ali Haluk Düzkalir, Selcuk Peker
Neurosurgery.2024; 94(4): 780. CrossRef
Deep learning based clinico-radiological model for paediatric brain tumor detection and subtype prediction
Abhishek Mahajan, Mayur Burrewar, Ujjwal Agarwal, Bharadwaj Kss, Apparao Mlv, Amrita Guha, Arpita Sahu, Amit Choudhari, Vivek Pawar, Vivek Punia, Sridhar Epari, Ayushi Sahay, Tejpal Gupta, Girish Chinnaswamy, Prakash Shetty, Aliasgar Moiyadi
Exploration of Targeted Anti-tumor Therapy.2023; : 669. CrossRef
Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies
Izac J. Findlay, Geoffry N. De Iuliis, Ryan J. Duchatel, Evangeline R. Jackson, Nicholas A. Vitanza, Jason E. Cain, Sebastian M. Waszak, Matthew D. Dun
Oncogene.2022; 41(4): 461. CrossRef
Clinical Efficacy of CyberKnife Radiosurgery for Adult Brainstem Glioma: 10 Years Experience at Tianjin CyberKnife Center and Review of the Literature
Jiaqi Zhang, Qun Liu, Zhiyong Yuan, Lujun Zhao, Xiaoguang Wang, Ping Wang
Frontiers in Oncology.2019;[Epub] CrossRef
Radiotherapy for brainstem gliomas in children and adults: A single‐institution experience and literature review
Kenji Yoshida, Nor Shazrina Sulaiman, Daisuke Miyawaki, Yasuo Ejima, Hideki Nishimura, Takeaki Ishihara, Yoshiro Matsuo, Ryo Nishikawa, Takashi Sasayama, Akira Hayakawa, Eiji Kohmura, Ryohei Sasaki
Asia-Pacific Journal of Clinical Oncology.2017;[Epub] CrossRef
Prognostic factors and survival in primary adult high grade brainstem astrocytoma: A population based study from 1973–2008
Mahua Dey, Yimo Lin, Stephanie Melkonian, Sandi Lam
Journal of Clinical Neuroscience.2014; 21(8): 1298. CrossRef
A treatment planning comparison of highly conformal radiation therapy for pediatric low-grade brainstem gliomas
Jeffrey V. Brower, Daniel J. Indelicato, Philipp R. Aldana, Eric Sandler, Ronny Rotondo, Nancy P. Mendenhall, Robert B. Marcus, Zhong Su
Acta Oncologica.2013; 52(3): 594. CrossRef
Stereotactic iodine-125 brachytherapy for treatment of inoperable focal brainstem gliomas of WHO grades I and II: feasibility and long-term outcome
Maximilian I. Ruge, Philipp Kickingereder, Thorsten Simon, Harald Treuer, Volker Sturm
Journal of Neuro-Oncology.2012; 109(2): 273. CrossRef

8,756 View
74 Download
8 Crossref

Usefulness of Additional Delayed Regional F-18 Fluorodeoxy-glucose Positron Emission Tomography in the Lymph Node Staging of Non-Small Cell Lung Cancer Patients: Young So, June-Key Chung, Jae Min Jeong, Dong Soo Lee, Myung Chul Lee; Cancer Res Treat. 2005;37(2):114-121. Published online April 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.2.114

Abstract PDF PubReader ePub

Purpose

In this study, we examined whether additional, delayed regional FDG PET scans could increase the accuracy of the lymph node staging of NSCLC patients.

Materials and Methods

Among 87 patients who underwent open thoracotomy or mediastinoscopic biopsy under the suspicion of NSCLC, 35 (32 NSCLC and 3 infectious diseases) who had visible lymph nodes on both preoperative whole body scan and regional FDG PET scan were included. The following 3 calculations were made for each biopsy-proven, visible lymph node: maximum SUV of whole body scan (WB SUV), maximum SUV of delayed chest regional scan (Reg SUV), and the percent change of SUV between WB and regional scans (% SUV Change). ROC curve analyses were performed for WB SUVs, Reg SUVs and % SUV Changes.

Results

Seventy lymph nodes (29 benign, 41 malignant) were visible on both preoperative whole bodyscan and regional scan. The means of WB SUVs, Reg SUVs and % SUV Changes of the 41 malignant nodes, 3.71±1.08, 5.18±1.60, and 42.59±33.41%, respectively, were all significantly higher than those of the 29 benign nodes, 2.45±0.73, 3.00±0.89, and 22.71±20.17%, respectively. ROC curve analysis gave sensitivity and specificity values of 80.5% and 82.8% at a cutoff of 2.89 (AUC 0.839) for WB SUVs, 87.8% and 82.8% at a cutoff of 3.61 (AUC 0.891) for Reg SUVs, and 87.8% and 41.4% at a cutoff of 12.3% (AUC 0.671) for % SUV Changes.

Conclusion

Additional, delayed regional FDG PET scans may improve the accuracy of lymph node staging of whole body FDG PET scan by providing additional criteria of Reg SUV and % SUV Change.

Citations

Citations to this article as recorded by

KSNM60 in Clinical Nuclear Oncology
Seung Hwan Moon, Young Seok Cho, Joon Young Choi
Nuclear Medicine and Molecular Imaging.2021; 55(5): 210. CrossRef
18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and backgro
Stephen P Povoski, Douglas A Murrey, Sabrina M Smith, Edward W Martin, Nathan C Hall
BMC Cancer.2014;[Epub] CrossRef
Fluorodeoxyglucose positron-emission tomography ratio in non-small cell lung cancer patients treated with definitive radiotherapy
Hyun-Cheol Kang, Hong-Gyun Wu, Tosol Yu, Hak Jae Kim, Jin Chul Paeng
Radiation Oncology Journal.2013; 31(3): 111. CrossRef
Defining the role of modern imaging techniques in assessing lymph nodes for metastasis in cancer: evolving contribution of PET in this setting
Thomas C. Kwee, Sandip Basu, Drew A. Torigian, Babak Saboury, Abass Alavi
European Journal of Nuclear Medicine and Molecular Imaging.2011; 38(7): 1353. CrossRef
Imaging Atherosclerosis in the Carotid Arteries with F-18-Fluoro-2-deoxy-D-glucose Positron Emission Tomography: Effect of Imaging Time after Injection on Quantitative Measurement
Minyoung Oh, Ji Young Kim, Kwang-Ho Shin, Seol Hoon Park, Jin-Sook Ryu, Jae Seung Kim, Hye-Jin Kim, Dong-Wha Kang, Dae Hyuk Moon
Nuclear Medicine and Molecular Imaging.2010; 44(4): 261. CrossRef

10,299 View
48 Download
5 Crossref

A Histone Deacetylase Inhibitor, Trichostatin A, Enhances Radiosensitivity by Abrogating G2/M Arrest in Human Carcinoma Cells: In Ah Kim, Jin Ho Kim, Jin Hee Shin, Il Han Kim, Jae Sung Kim, Hong-Gyun Wu, Eui Kyu Chie, Yong Ho Kim, Bo-Kyung Kim, Semie Hong, Seok Won Park, Sung Whan Ha, Charn Il Park; Cancer Res Treat. 2005;37(2):122-128. Published online April 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.2.122

Abstract PDF PubReader ePub

Purpose

Histone deacetylase inhibitors (HDIs) are emerging as potentially useful components in anticancer therapy. In this study, we tried to confirm the radiosensitizing effect of trichostatin A (TSA) on a panel of human carcinoma cell lines and elucidate its mechanism of interaction.

Materials and Methods

A549, HeLa and Caski cells were exposed to TSA for 18 hr prior to irradiation, and the cell survival then measured using a clonogenic assay. Western blot and flow cytometric analyses, for histone acetylation, and cell cycle and apoptosis, respectively, were also performed.

Results

TSA increased the acetylation of histone H3. The pretreatment of TSA consistently radiosensitized all three cell lines. The SF2 (surviving fraction at 2 Gy) of TSA-treated cells was significantly lower than that of mock treated cells. The SER (sensitizer enhancement ratio) increased in all 3 cell lines, in concentration dependent manners. The TSA treated cells showed abrogation of radiation-induced G2/M arrest, in a concentration dependent manner.

Conclusion

The pretreatment of TSA enhanced the radiosensitivity of a panel of human carcinoma cells, which was attributed, in part, to the abrogation of radiation-induced G2/M arrest.

Citations

Citations to this article as recorded by

Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer
Yijun Xie, Di Xiao, Duo Li, Mei Peng, Wei Peng, Huaxin Duan, Xiaoping Yang
Frontiers in Oncology.2024;[Epub] CrossRef
Radiosensitizing effect of dendrosomal nanoformulation of curcumin on cancer cells
Tahereh Jalali Varnamkhasti, Meisam Jafarzadeh, Majid Sadeghizadeh, Mahdi Aghili
Pharmacological Reports.2022; 74(4): 718. CrossRef
Pharmacological Properties of Trichostatin A, Focusing on the Anticancer Potential: A Comprehensive Review
Abdelhakim Bouyahya, Nasreddine El Omari, Mohamed Bakha, Tarik Aanniz, Naoual El Menyiy, Naoufal El Hachlafi, Aicha El Baaboua, Mohamed El-Shazly, Mohammed Merae Alshahrani, Ahmed Abdullah Al Awadh, Learn-Han Lee, Taoufiq Benali, Mohammad S. Mubarak
Pharmaceuticals.2022; 15(10): 1235. CrossRef
Low Dose of Trichostatin A Improves Radiation Resistance by Activating Akt/Nrf2-Dependent Antioxidation Pathway in Cancer Cells
Fengqiu Zhang, Changsheng Shao, Zhu Chen, Yalin Li, Xumiao Jing, Qing Huang
Radiation Research.2021;[Epub] CrossRef
Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
Ying Li, Zhijun Zhan, Xuemin Yin, Shujun Fu, Xiyun Deng
Frontiers in Oncology.2021;[Epub] CrossRef
Is level of acetylation directly correlated to radiation sensitivity of cancer cell?
Fengqiu Zhang, Zhu Chen, Changsheng Shao, Qing Huang
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis.2019; 813: 13. CrossRef
Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53
Manuela Terranova-Barberio, Biagio Pecori, Maria Serena Roca, Serena Imbimbo, Francesca Bruzzese, Alessandra Leone, Paolo Muto, Paolo Delrio, Antonio Avallone, Alfredo Budillon, Elena Di Gennaro
Journal of Experimental & Clinical Cancer Research.2017;[Epub] CrossRef
Histone Acetylation Induced Transformation of B-DNA to Z-DNA in Cells Probed through FT-IR Spectroscopy
Fengqiu Zhang, Qing Huang, Jingwen Yan, Zhu Chen
Analytical Chemistry.2016; 88(8): 4179. CrossRef
Cell-based multi-substrate assay coupled to UHPLC-ESI-MS/MS for a quick identification of class-specific HDAC inhibitors
Vincent Zwick, Claudia Simões-Pires, Muriel Cuendet
Journal of Enzyme Inhibition and Medicinal Chemistry.2016; 31(sup1): 209. CrossRef
Assessment of the Effect of Trichostatin A on HeLa Cells through FT-IR Spectroscopy
Fengqiu Zhang, Qing Huang, Jingwen Yan, Xin Zhang, Jianxin Li
Analytical Chemistry.2015; 87(4): 2511. CrossRef
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
Ahrum Min, Seock-Ah Im, Debora Keunyoung Kim, Sang-Hyun Song, Hee-Jun Kim, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, Do-Youn Oh, Tae-You Kim, Mark J O’Connor, Yung-Jue Bang
Breast Cancer Research.2015;[Epub] CrossRef
CD44 is a biomarker associated with human prostate cancer radiation sensitivity
WeiWei Xiao, Peter H. Graham, Carl A. Power, Jingli Hao, John H. Kearsley, Yong Li
Clinical & Experimental Metastasis.2012; 29(1): 1. CrossRef
Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells
Han Sang Kim, Sang Cheol Kim, Sun Jeong Kim, Chan Hee Park, Hei-Cheul Jeung, Yong Bae Kim, Joong Bae Ahn, Hyun Cheol Chung, Sun Young Rha
BMC Genomics.2012;[Epub] CrossRef
In vivoRadiosensitization Effect of HDAC Inhibitor, SK-7041 on RIF-1 Cell Line
Eui Kyu Chie, Jin Hee Shin, In Ah Kim, Il Han Kim
The Journal of the Korean Society for Therapeutic Radiology and Oncology.2010; 28(4): 219. CrossRef
Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: Potential role of histone deacetylase 6
In Ah Kim, Mina No, Jang Mi Lee, Jin Hee Shin, Jee Sun Oh, Eun Jung Choi, Il Han Kim, Peter Atadja, Eric J. Bernhard
Radiotherapy and Oncology.2009; 92(1): 125. CrossRef
Histone Deacetylase Inhibitor–Mediated Radiosensitization of Human Cancer Cells: Class Differences and the Potential Influence of p53
In Ah Kim, Jin Hee Shin, Il Han Kim, Jin Ho Kim, Jae Sung Kim, Hong Gyun Wu, Eui Kyu Chie, Sung Whan Ha, Charn Il Park, Gary D. Kao
Clinical Cancer Research.2006; 12(3): 940. CrossRef

12,628 View
73 Download
16 Crossref

Case Reports

Lymph Node Metastases of Prostatic Adenocarcinoma in the Mesorectum in Patients with Rectal Cancer: In Ja Park, Hee Cheol Kim, Chang Sik Yu, Choung Soo Kim, Jung Sun Kim, Jin Cheon Kim; Cancer Res Treat. 2005;37(2):129-132. Published online April 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.2.129

Abstract PDF PubReader ePub

Lymph node involvement is the most important prognostic factor of rectal cancer. Cancer originating from sites other than the rectum rarely metastasizes to the mesorectal lymph node. We report a rectal cancer patient with a synchronous metastatic prostatic carcinoma to the mesorectal lymph node.

Citations

Citations to this article as recorded by

A Case of Prostate Cancer Diagnosed by the Discovery of Pararectal Lymph Node Metastases during Sigmoid Colon Cancer Surgery
Daiki KATO, Chieko KITAMURA, Jun YAMADA
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2023; 84(9): 1515. CrossRef
A Case of Rectal Cancer with Lymph Node Metastasis of Prostate Cancer in the Mesorectum after Radical Prostatectomy
Teruhisa UDAGAWA, Yu SUZUKI, Yasushi ITO, Yoshihisa TAMATE, Naoki YANAGAWA, Takashi KAMEI
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2022; 83(4): 775. CrossRef
Two Cases of Colorectal Cancer with Mesenteric Lymph Node Metastasis Derived from Prostatic Cancer
Fumitaka Asahara, Hirotoshi Hasegawa, Shutaro Suda, Emima Bekku, Kazuhiko Hashimoto, Aya Sasaki, Junichi Matsui
The Japanese Journal of Gastroenterological Surgery.2020; 53(1): 61. CrossRef
Metastasization of mesorectal lymph nodes by a prostatic adenocarcinoma
J.J. Arenal, A. Torres, C. Tinoco, M.A. Citores, C. Benito, B. Madrigal, A. Vara
Human Pathology: Case Reports.2015; 2(2): 42. CrossRef

9,665 View
104 Download
4 Crossref

Carboxypeptidase-G2 Rescue in a Patient with High Dose Methotrexate-induced Nephrotoxicity: Eun Sil Park, Kyung Hee Han, Hyoung Soo Choi, Hee Young Shin, Hyo Seop Ahn; Cancer Res Treat. 2005;37(2):133-135. Published online April 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.2.133

Abstract PDF PubReader ePub

A 13 year-old girl with osteosarcoma and pulmonary tumor recurrence developed acute renal failure following high dose methotrexate (12 g/m²) therapy, she had previously tolerated high dose methotrexate and her renal and hepatic functions were normal. Briefly, 48 hours after beginning methotrexate infusion her methotrexate concentration and creatinine level were 1338.8 µM/L and 5.8 mg/dl, respectively. Grade IV oral mucositis and neutropenia with fever developed at 144 hours after MTX infusion. Hydration and alkalinization were continued and leucovorin rescue was intensified based on the plasma MTX concentrations. Plasma exchange was performed twice and hemodialysis 3 times without problems, but methotraxate and creatinine levels remained high, 91.9 µM/L, and 2.5 mg/dl, respectively. After 3 courses of hemodialysis carboxypeptidase-G2 (CPDG2) was administered at 50 U/kg, intravenously over 5 minutes. After 15 minutes of CPDG2 (Voraxaze™) infusion, her plasma MTX concentration was 0.91 µM/L and no rebound elevation or side effects developed. Thirteen days post-MTX infusion her renal function had normalized. We report here our experience of a dramatic methotrexate level reduction caused by CPDG2 administration.

Citations

Citations to this article as recorded by

Extracorporeal Treatment for Methotrexate Poisoning
Marc Ghannoum, Darren M. Roberts, David S. Goldfarb, Jesper Heldrup, Kurt Anseeuw, Tais F. Galvao, Thomas D. Nolin, Robert S. Hoffman, Valery Lavergne, Paul Meyers, Sophie Gosselin, Tudor Botnaru, Karine Mardini, David M. Wood
Clinical Journal of the American Society of Nephrology.2022; 17(4): 602. CrossRef
Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients
Jeffrey R. Scott, Yinmei Zhou, Cheng Cheng, Deborah A. Ward, Hope D. Swanson, Alejandro R. Molinelli, Clinton F. Stewart, Fariba Navid, Sima Jeha, Mary V. Relling, Kristine R. Crews
Pediatric Blood & Cancer.2015; 62(9): 1518. CrossRef
Resumption of high‐dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients
Anthony M. Christensen, Jennifer L. Pauley, Alejandro R. Molinelli, John C. Panetta, Deborah A. Ward, Clinton F. Stewart, James M. Hoffman, Scott C. Howard, Ching‐Hon Pui, Alberto S. Pappo, Mary V. Relling, Kristine R. Crews
Cancer.2012; 118(17): 4321. CrossRef

8,452 View
62 Download
3 Crossref

First
Prev
Page of 1
Next
Last

Previous issues